Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC 321: H1 Stabilized Stem Ferritin Vaccine in Healthy Adults
NCT03814720Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2019
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of H1ssF in influenza (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms at 7 days, Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms at 7 days and 5 more. Started Apr 2019; status: completed.
02
Drugs
H1ssF
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03814720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03814720.